Nafamostat Mesilate Attenuates Postreperfusion Syndrome during Liver Transplantation

Postreperfusion syndrome (PRS), an acute decrease in blood pressure after reperfusion of the liver graft, occurs frequently during liver transplantation surgery. We supposed that the activation of the kallikrein–kinin system leading to extensive systemic vasodilatation was a possible cause. The effect of pretreatment with nafamostat mesilate (NM), a broad spectrum serine protease inhibitor, on the occurrence of PRS was evaluated. Sixty‐two adult liver recipients were randomized to receive an intravenous bolus of either 0.02 mg/kg of NM (NM group, n = 31) or an equal volume of normal saline (control group, n = 31) just before reperfusion of the liver graft. Occurrence of PRS and intraoperative use of vasoactive drugs were compared between the two groups. Postoperative recovery was also compared. PRS was significantly less frequent (48% vs. 81%, p = 0.016) requiring less vasopressors in the NM group compared to the control group. The NM group also showed faster recovery of the mean arterial pressure. Perioperative laboratory values were similar between the two groups. Pretreatment with 0.02 mg/kg of NM immediately before reperfusion decreases the frequency of PRS and vasopressor requirements during the reperfusion period in liver transplantation.

[1]  M. Ramsay,et al.  Postreperfusion syndrome during liver transplantation for cirrhosis: Outcome and predictors , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  J. Gagne,et al.  Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta‐analysis of epidemiologic studies , 2009, Pharmacoepidemiology and drug safety.

[3]  M. Gwak,et al.  Greater hemodynamic instability with histidine-tryptophan-ketoglutarate solution than University of Wisconsin solution during the reperfusion period in living donor liver transplantation. , 2008, Transplantation proceedings.

[4]  R. Martineau,et al.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. , 2008, The New England journal of medicine.

[5]  A. Marcos,et al.  The impact of postreperfusion syndrome on short‐term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[6]  B. Gridelli,et al.  Comparison of two different techniques of reperfusion in adult orthotopic liver transplantation , 2006, Clinical transplantation.

[7]  Kniepeiss Daniela,et al.  Influence of retrograde flushing via the caval vein on the post‐reperfusion syndrome in liver transplantation , 2004, Clinical transplantation.

[8]  Y. Tokat,et al.  Causes of postreperfusion syndrome in living or cadaveric donor liver transplantations. , 2003, Transplantation proceedings.

[9]  J. Findlay,et al.  Aprotinin reduces vasoactive medication use during adult liver transplantation. , 2003, Journal of clinical anesthesia.

[10]  F. Gejyo,et al.  Anaphylactoid Reaction Induced by a Protease Inhibitor, Nafamostat Mesilate, following Nine Administrations in a Hemodialysis Patient , 2000, Nephron.

[11]  H. Putter,et al.  Reduced Need for Vasopressors in Patients Receiving Aprotinin during Orthotopic Liver Transplantation , 2000, Anesthesiology.

[12]  P. Parrilla,et al.  Influence of surgical technique on postreperfusion syndrome during liver transplantation. , 1999, Transplantation proceedings.

[13]  M. Nakane,et al.  A potential mechanism of propofol-induced pain on injection based on studies using nafamostat mesilate. , 1999, British journal of anaesthesia.

[14]  L. Boscá,et al.  Presence of a nitric oxide synthase inhibitor in the graft efflux during reperfusion in human liver transplantation , 1999, Clinical transplantation.

[15]  K. Watanabe,et al.  Nafamostat mesilate, a kallikrein inhibitor, prevents pain on injection with propofol. , 1998, British journal of anaesthesia.

[16]  D. Chemla,et al.  In Vitro Negative Inotropic Effect of Plasma Collected at the Time of Reperfusion in Humans undergoing Liver Transplantation , 1997, Anesthesiology.

[17]  A. Bengtsson,et al.  Neutrophil and macrophage activation and anaphylatoxin formation in orthotopic liver transplantation without the use of veno‐venous bypass , 1996, Acta anaesthesiologica Scandinavica.

[18]  K. Tan,et al.  Improved haemodynamic stability with administration of aprotinin during orthotopic liver transplantation. , 1995, British journal of anaesthesia.

[19]  P. Hayes,et al.  Effect of the serine protease inhibitor, aprotinin, on systemic haemodynamics and renal function in patients with hepatic cirrhosis and ascites. , 1994, Clinical science.

[20]  M. Pinsky,et al.  Postreperfusion syndrome: hypotension after reperfusion of the transplanted liver. , 1993, Journal of critical care.

[21]  P. Albaladéjo,et al.  The failure of venovenous bypass to prevent graft liver postreperfusion syndrome. , 1992, Transplantation.

[22]  J. Römisch,et al.  Comparative study on the in vitro effectiveness of antithrombotic agents. , 1991, Thrombosis research.

[23]  M. Pinsky,et al.  Postreperfusion syndrome: cardiovascular collapse following hepatic reperfusion during liver transplantation. , 1987, Transplantation proceedings.

[24]  F. Marceau,et al.  The kallikrein-kinin system: current and future pharmacological targets. , 2005, Journal of pharmacological sciences.

[25]  平島知圭.  Nafamostat mesilate の先発品と後発品の比較について , 2004 .

[26]  J. Findlay,et al.  Aprotinin and reduced epinephrine requirements in orthotopic liver transplantation. , 2002, Anesthesiology.